45.38
Sionna Therapeutics Inc (SION) 最新ニュース
SION|SION|Price:45.700|Chg%:+1.640 - TradingKey
Sionna Therapeutics Slides as Lofty Valuation Deflates - TipRanks
Sionna Therapeutics Inc. (SION) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SION Jumps As Sionna Therapeutics Stock Extends Breakout - StocksToTrade
SION Jumps As Sionna Therapeutics Draws Trader Attention - StocksToTrade
Sionna Therapeutics (SION) Sees 9.2% Surge in Stock Price - GuruFocus
Sionna Therapeutics stock hits all-time high at 48.66 USD - Investing.com
Sionna Therapeutics stock hits all-time high at 48.66 USD By Investing.com - Investing.com South Africa
Sionna Therapeutics Surges As CF Trial Data Loom - TipRanks
Orbimed Advisors LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Sionna Therapeutics, Inc. Common Stock (SION) Stock Price Today: $42.59 - Gotrade
Wedbush initiates coverage of Sionna Therapeutics (SION) with outperform recommendation - MSN
Sionna Therapeutics(SION.US) Director Sells US$3.85 Million in Common Stock - Moomoo
Form 4 Sionna Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
OrbiMed Advisors, Sionna director, sells $3.85 million in stock - Investing.com UK
Sionna Therapeutics director Peter Thompson sells $3.85m in stock - Investing.com
Sionna Therapeutics Insider Sold Shares Worth $3,854,281, According to a Recent SEC Filing - Moomoo
Sionna Therapeutics director Peter Thompson sells $3.85m in stock By Investing.com - Investing.com Canada
Sionna Therapeutics CLO Jennifer Fitzpatrick sells $446k in stock - Investing.com
Sionna Therapeutics CLO Jennifer Fitzpatrick sells $446k in stock By Investing.com - Investing.com Nigeria
Form 4 Sionna Therapeutics Inc For: 7 July By Investing.com - Investing.com Nigeria
Sionna Therapeutics (SION) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Is Sionna Therapeutics (SION) Undervalued Or Already Priced In As Index Changes Draw Focus? - simplywall.st
ETFs Investing in Sionna Therapeutics, Inc. Stocks - TradingView
SIONSionna Therapeutics Inc Options - Finviz
Form 4 Sionna Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Sionna Therapeutics director Thompson sells $5.27m in stock By Investing.com - Investing.com South Africa
Sionna Therapeutics director Thompson sells $5.27m in stock - Investing.com
Sionna Therapeutics Inc. (SION) Q1 2026 Earnings: Clinical-Stage Biotech Misses EPS Estimates Amid No RevenueROE Trend Analysis - dars.gov.et
Enterprise value to EBITDA forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to EBIT forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to revenue forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to earnings forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to sales forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment (SION) - Seeking Alpha
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell 3000E Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell Microcap Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM:SION) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Sionna Therapeutics, Inc. Actuals & Estimates (NASDAQ:SION) - TradingView
SION Forecast — Price Target — Prediction for 2027 - TradingView
JonesTrading Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $63 - Moomoo
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO) - The Globe and Mail
Citizens reiterates Sionna Therapeutics stock rating ahead of summer data By Investing.com - Investing.com Nigeria
Guggenheim Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Sionna Therapeutics: Buy Rating Reiterated on NBD1-Focused CF Strategy; $60 Price Target Maintained - TipRanks
Sionna Stockholders Reelect Directors, Ratify Deloitte as Auditor - The Globe and Mail
LifeSci Capital Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $60 - Moomoo
大文字化:
|
ボリューム (24 時間):